Synergy Chc CORP

Synergy CHC Corp. announced that Costco Wholesale Corporation will discontinue carrying its FOCUSfactor products, a move expected to materially impact the company's business and financial condition.

Synergy CHC Corp. stockholders approved amendments to the 2024 Equity Incentive Plan, increasing share availability and allowing award repricing.

Synergy CHC Corp. received a notice from Nasdaq indicating its common stock has fallen below the $1.00 minimum bid price requirement, triggering a compliance period.

Synergy CHC Corp. reported first quarter 2026 results with a significant increase in functional beverage revenue, though overall revenue declined year-over-year due to a non-recurring license fee and inventory challenges.

Synergy CHC Corp. has entered into a $36 million equity purchase agreement with Hudson Global Ventures, LLC, along with a common stock purchase warrant.

Synergy CHC Corp. has amended its term loan credit agreement, adjusting payment schedules and covenants, and issued a common stock purchase warrant to a lender.

Synergy CHC Corp. reported a significant decrease in revenue for the first quarter of 2026, driven by lower product sales, alongside an increased net loss.

Synergy CHC Corp. reported increased Q3 revenue and gross profit, significantly reduced liabilities through debt settlements and a new senior loan, and completed an IPO.

Synergy CHC Corp. reported a significant increase in net income for Q2 2025, driven by new license revenue and substantial gains from debt settlements, despite a decline in product sales.

Synergy CHC Corp. announces a profitable first quarter for 2025, driven by a license agreement and cost management, despite a decrease in product sales revenue.

Synergy CHC Corp. reports a net income of $2.019 million for the nine months ended September 30, 2024, despite a decrease in revenue compared to the same period in 2023.

Synergy CHC Corp.'s 2024 results reflect a decrease in revenue due to a FOCUSfactor rebranding, alongside strategic debt restructuring and ongoing efforts to expand into new markets.

Alfred Baumeler, Director and President of Synergy CHC Corp., reports on stock option grants and modifications.

Jaime Fickett, Chief Financial Officer of Synergy CHC Corp., reported a modification to stock options, adjusting exercise prices and vesting schedules.

Synergy CHC Corp. CEO and Chairman Jack Ross reports on stock option transactions, including a modification to an existing option grant.

Director Nitin Kaushal acquired 306,433 restricted stock units in Synergy CHC Corp. which vested immediately upon grant.

Director Teresa Brigid Thompson acquired 25,824 restricted stock units in Synergy CHC Corp. as part of the company's 2024 Equity Incentive Plan.

Synergy CHC Corp. granted 150,000 stock options to President and Director Alfred Baumeler with an exercise price of $2.38.

Synergy CHC Corp. has filed a definitive proxy statement with the SEC.

Synergy CHC Corp. is holding its 2025 annual meeting of stockholders to vote on key proposals including the election of directors, ratification of auditors, an amendment to the equity incentive plan, and authorization to issue preferred stock.

Synergy CHC Corp. filed an S-1 registration statement for the resale of up to 101.71 million shares by Hudson Global Ventures, LLC, and to register shares for a potential $36 million Equity Line of Credit.

Synergy CHC Corp. filed an S-1 registration statement to offer up to 1.28 million shares of common stock at $3.92 per share, aiming to raise approximately $4.4 million for working capital and general corporate purposes.

Synergy CHC Corp. has filed a registration statement to increase the aggregate number of shares of common stock offered by 172,500 shares.

Synergy CHC Corp. is moving forward with its IPO plans, offering 1,000,000 shares of common stock with an estimated price range of $9.00 to $11.00.

Synergy CHC Corp. is seeking to list on the Nasdaq Global Market through an offering of 1,000,000 shares of common stock, with an estimated price range of $9.00 to $11.00 per share.

Synergy CHC Corp. files an amendment to its S-1 registration statement, aiming to raise approximately $20 million through an IPO to fuel growth initiatives.

Knight Therapeutics Inc. has reported an increased beneficial ownership stake of 19.90% in Synergy CHC Corp., including shares held directly and through warrants.

Knight Therapeutics Inc. has reported a 17.03% beneficial ownership stake in Synergy CHC Corp., totaling 1,482,844 shares, as of December 31, 2024.